Table 2 Participants medication of HF (n = 448)
From: Managing patients with heart failure: contemporary real-world experience
Total-448 n (%) | Hospital Group-173 n (%) | Clinic Group-275 n (%) | P-Value | |
|---|---|---|---|---|
Beta-blockers | 381 (85) | 132 (76.3) | 249 (90.5) | < 0.001 |
Hydralazine | 33 (7.4) | 26 (15) | 7 (2.5) | < 0.001 |
Nitrates | 139 (31) | 85 (49.1) | 54 (19.6) | < 0.001 |
Diuretics | 347 (77.5) | 163 (94.2) | 184 (66.9) | < 0.001 |
MRA | < 0.001 | |||
No | 316 (70.5) | 169 (97.7) | 147 (53.5) | |
Aldactone | 129 (28.8) | 4 (2.3) | 125 (45.5) | |
Eplerenone | 3 (0.7) | 0 | 3 (1.1) | |
ARBs & ACE inhibitors | < 0.001 | |||
No | 97 (21.6) | 60 (34.7) | 37 (13.5) | |
ACE inhibitors | 258 (57.6) | 77 (44.5) | 181 (65.8) | |
ARBs | 93 (20.8) | 36 (20.8) | 57 (20.7) |